MRK - Merck's Keytruda gains approval for additional endometrial carcinoma indication
2024-06-17 13:47:48 ET
More on Merck
- Dividends And Innovation: Why Merck Is A Healthcare Stock Worth Buying
- Merck shares traded in the green for seven straight days
- AstraZeneca dominates, Merck’s Keytruda beaten as ASCO 2024 concludes
- Merck & Co., Inc. (MRK) Investor Event at ASCO 2024 (Transcript)
- Merck & Co., Inc. (MRK) Goldman Sachs 45th Annual Global Healthcare Conference - (Transcript)